Skip to Content

Join the 'Postoperative Ocular Inflammation' group to help and get support from people like you.

Postoperative Ocular Inflammation News

Sun Pharma Receives FDA Approval For BromSite (bromfenac ophthalmic solution)

Posted 12 Apr 2016 by Drugs.com

Mumbai, April 09, 2016: Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE:524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced that one of its wholly owned subsidiaries has received approval from USFDA for its New Drug Application (NDA) related to BromSite™ (bromfenac ophthalmic solution) 0.075% for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. BromSite™ is the first non-steroidal antiinflammatory drug (NSAID) approved by the USFDA to prevent pain and treat inflammation in the eye for patients undergoing cataract surgery; other NSAIDs in this class are currently indicated for the treatment of inflammation and reduction of pain. BromSite™ developed by InSite Vision, is the first bromfenac ophthalmic solution formulated in DuraSite™, a polymer ... Read more

Related support groups: Surgery, Cataract, Postoperative Ocular Inflammation, BromSite, Bromfenac

Bausch + Lomb Receives FDA Approval for Prolensa

Posted 8 Apr 2013 by Drugs.com

MADISON, NJ - Bausch + Lomb, the global eye health company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for Prolensa (bromfenac ophthalmic solution) 0.07 percent prescription eye drop, an innovative once-daily nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Prolensa will be available in 1.6ml and 3ml bottle sizes. Prolensa provides powerful and rapid resolution of inflammation and pain by leveraging the unique potency of the bromfenac molecule in a formulation designed to facilitate ocular penetration. The advanced formulation allows for a lower concentration of bromfenac in a once daily dosing regimen. Prolensa is a solution that does not require shaking to deliver a consistent dose in each ... Read more

Related support groups: Postoperative Ocular Inflammation, Bromfenac Ophthalmic

ISTA Pharmaceuticals Receives FDA Approval for Bromday

Posted 20 Oct 2010 by Drugs.com

IRVINE, Calif., Oct. 16 /PRNewswire-FirstCall/ – ISTA Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Bromday (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. ISTA expects to launch Bromday (formerly referred to as XiDay) prior to the end of 2010. "Bromday is the only once-daily ophthalmic nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. We believe the convenience of a once-daily eye drop will help with treatment compliance and benefit patients recovering from cataract surgery," stated Vicente Anido, Jr., ... Read more

Related support groups: Postoperative Ocular Inflammation, Bromfenac Ophthalmic

Ask a Question

Further Information

Related Condition Support Groups

Ophthalmic Surgery

Related Drug Support Groups

Pred Forte, Nevanac, Durezol, Lotemax, Omnipred, Acular, Alrex, loteprednol, Econopred Plus, view more... Bromday, Econopred, Acuvail, Xibrom, dexamethasone / tobramycin, Pred Mild, Prednisol, Prolensa, Ilevro, BromSite, Acular LS, difluprednate, Vexol, ketorolac / phenylephrine, Ocufen, Omidria, nepafenac, Acular PF, rimexolone, AK-Pred, Inflamase Mild, Inflamase Forte, Ocu-Pred, Ocu-Pred Forte, Ocu-Pred-A, Voltaren Ophthalmic